p53-expression in patients with renal cell carcinoma correlates with a higher probability of disease progression and increased cancer-specific mortality after surgery but does not enhance the predictive accuracy of robust outcome models-Reference-Cited by-同舟云学术

p53-expression in patients with renal cell carcinoma correlates with a higher probability of disease progression and increased cancer-specific mortality after surgery but does not enhance the predictive accuracy of robust outcome models

Published:2018-03 Issue:3 Volume:36 Page:94.e15-94.e21
ISSN:1078-1439
Container-title:Urologic Oncology: Seminars and Original Investigations
language:en
Short-container-title:Urologic Oncology: Seminars and Original Investigations

Author:

Morshaeuser Laura,May Matthias,Burger Maximilian,Otto Wolfgang,Hutterer Georg C.,Pichler Martin,Klatte Tobias,Wild Peter,Buser Lorenz,Brookman-May Sabine

Publisher

Elsevier BV

Subject

Urology,Oncology

Reference27 articles.

1. European Network of Cancer Registries. Eurocim version 4.0. European incidence database V2.3, 730 entity dictionary (2001), Lyon, 2001.

2. Epidemiology of renal cell carcinoma;Lindblad;Scand J Surg,2004

3. Risk group assessment and clinical outcome algorithm to predict the natural history of patients with surgically resected renal cell carcinoma;Zisman;J Clin Oncol,2002

4. Features Associated with Recurrence Beyond 5 Years After Nephrectomy and Nephron-Sparing Surgery for Renal Cell Carcinoma: Development and Internal Validation of a Risk Model (PRELANE score) to Predict Late Recurrence Based on a Large Multicenter Database (CORONA/SATURN Project)

5. Outcomes and clinicopathologic variables associated with late recurrence after nephrectomy for localized renal cell carcinoma;Kim;Urology,2011

Cited by 9 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Prognostic factors in Latin American patients with localized and advanced renal cell carcinoma: a literature review;AME Medical Journal;2023-09

2. P53 and survivin expression in renal cell carcinoma;Urology Annals;2023

3. p53 and Its Isoforms in Renal Cell Carcinoma—Do They Matter?;Biomedicines;2022-06-06

4. Kidney cancer biomarkers and targets for therapeutics: survivin (BIRC5), XIAP, MCL-1, HIF1α, HIF2α, NRF2, MDM2, MDM4, p53, KRAS and AKT in renal cell carcinoma;Journal of Experimental & Clinical Cancer Research;2021-08-12

5. Amarogentin Inhibits Liver Cancer Cell Angiogenesis after Insufficient Radiofrequency Ablation via Affecting Stemness and the p53-Dependent VEGFA/Dll4/Notch1 Pathway;BioMed Research International;2020-10-20